The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial

BACKGROUND: We evaluated the effects of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids enriched fish oil (FO) on nutritional and immunological parameters of treatment naïve breast cancer patients. METHODS: In a randomized double blind controlled trial, the FO group (FG) patients were supplem...

Descripción completa

Detalles Bibliográficos
Autores principales: Paixão, Elemárcia Martins da Silva, Oliveira, Ana Carolina de M., Pizato, Nathalia, Muniz-Junqueira, Maria Imaculada, Magalhães, Kelly G., Nakano, Eduardo Yoshio, Ito, Marina K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653994/
https://www.ncbi.nlm.nih.gov/pubmed/29061183
http://dx.doi.org/10.1186/s12937-017-0295-9
_version_ 1783273319598915584
author Paixão, Elemárcia Martins da Silva
Oliveira, Ana Carolina de M.
Pizato, Nathalia
Muniz-Junqueira, Maria Imaculada
Magalhães, Kelly G.
Nakano, Eduardo Yoshio
Ito, Marina K.
author_facet Paixão, Elemárcia Martins da Silva
Oliveira, Ana Carolina de M.
Pizato, Nathalia
Muniz-Junqueira, Maria Imaculada
Magalhães, Kelly G.
Nakano, Eduardo Yoshio
Ito, Marina K.
author_sort Paixão, Elemárcia Martins da Silva
collection PubMed
description BACKGROUND: We evaluated the effects of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids enriched fish oil (FO) on nutritional and immunological parameters of treatment naïve breast cancer patients. METHODS: In a randomized double blind controlled trial, the FO group (FG) patients were supplemented with 2 g/ day of FO concentrate containing 1.8 g of n-3 fatty acids during 30 days. The placebo group (PG) received 2 g/ day of mineral oil. At baseline and after the intervention, plasma levels of n-3 fatty acids, dietary intake, weight, body composition, biochemical and immunological markers were assessed. RESULTS: At the end of the intervention period, no between group differences were observed regarding anthropometric parameters. There was a significant increase in the plasma phospholipid EPA (p = 0.004), DHA (p = 0.007) of the FG patients. In FG patients the percentages of peripheral blood CD4(+) T lymphocytes and serum high sensitivity C-reactive protein (hsCRP) levels were maintained while in PG patients there was a significant increase in hsCRP (p = 0.024). We also observed a significant reduction in the percentage of CD4(+) T lymphocytes in the peripheral blood (p = 0.042) of PG patients. No changes in serum proinflammatory cytokine and prostaglandin E(2) levels were observed. CONCLUSIONS: Supplementation of newly diagnosed breast cancer patients with EPA and DHA led to a significant change in the composition of plasma fatty acids, maintained the level of CD4(+) T cells and serum levels of hsCRP, suggestive of a beneficial effect on the immune system and less active inflammatory response. TRIAL REGISTRATION: Brazilian Clinical Trials Registry (REBEC): RBR-2b2hqh. Registered 29 April 2013, retrospectively registered.
format Online
Article
Text
id pubmed-5653994
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56539942017-10-26 The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial Paixão, Elemárcia Martins da Silva Oliveira, Ana Carolina de M. Pizato, Nathalia Muniz-Junqueira, Maria Imaculada Magalhães, Kelly G. Nakano, Eduardo Yoshio Ito, Marina K. Nutr J Research BACKGROUND: We evaluated the effects of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids enriched fish oil (FO) on nutritional and immunological parameters of treatment naïve breast cancer patients. METHODS: In a randomized double blind controlled trial, the FO group (FG) patients were supplemented with 2 g/ day of FO concentrate containing 1.8 g of n-3 fatty acids during 30 days. The placebo group (PG) received 2 g/ day of mineral oil. At baseline and after the intervention, plasma levels of n-3 fatty acids, dietary intake, weight, body composition, biochemical and immunological markers were assessed. RESULTS: At the end of the intervention period, no between group differences were observed regarding anthropometric parameters. There was a significant increase in the plasma phospholipid EPA (p = 0.004), DHA (p = 0.007) of the FG patients. In FG patients the percentages of peripheral blood CD4(+) T lymphocytes and serum high sensitivity C-reactive protein (hsCRP) levels were maintained while in PG patients there was a significant increase in hsCRP (p = 0.024). We also observed a significant reduction in the percentage of CD4(+) T lymphocytes in the peripheral blood (p = 0.042) of PG patients. No changes in serum proinflammatory cytokine and prostaglandin E(2) levels were observed. CONCLUSIONS: Supplementation of newly diagnosed breast cancer patients with EPA and DHA led to a significant change in the composition of plasma fatty acids, maintained the level of CD4(+) T cells and serum levels of hsCRP, suggestive of a beneficial effect on the immune system and less active inflammatory response. TRIAL REGISTRATION: Brazilian Clinical Trials Registry (REBEC): RBR-2b2hqh. Registered 29 April 2013, retrospectively registered. BioMed Central 2017-10-23 /pmc/articles/PMC5653994/ /pubmed/29061183 http://dx.doi.org/10.1186/s12937-017-0295-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Paixão, Elemárcia Martins da Silva
Oliveira, Ana Carolina de M.
Pizato, Nathalia
Muniz-Junqueira, Maria Imaculada
Magalhães, Kelly G.
Nakano, Eduardo Yoshio
Ito, Marina K.
The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
title The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
title_full The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
title_fullStr The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
title_full_unstemmed The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
title_short The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
title_sort effects of epa and dha enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653994/
https://www.ncbi.nlm.nih.gov/pubmed/29061183
http://dx.doi.org/10.1186/s12937-017-0295-9
work_keys_str_mv AT paixaoelemarciamartinsdasilva theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT oliveiraanacarolinadem theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT pizatonathalia theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT munizjunqueiramariaimaculada theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT magalhaeskellyg theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT nakanoeduardoyoshio theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT itomarinak theeffectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT paixaoelemarciamartinsdasilva effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT oliveiraanacarolinadem effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT pizatonathalia effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT munizjunqueiramariaimaculada effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT magalhaeskellyg effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT nakanoeduardoyoshio effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial
AT itomarinak effectsofepaanddhaenrichedfishoilonnutritionalandimmunologicalmarkersoftreatmentnaivebreastcancerpatientsarandomizeddoubleblindcontrolledtrial